v3.26.1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2026
Accounting Policies [Abstract]  
Schedule of Concentration, Percentage of Gross Revenues
The following table summarizes customers that represent 10% or greater of our consolidated total gross revenues:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Bayer (as described in Note 10)***30.1%
Alexion (as described in Note 10)*22.3%*12.0%
Customer A18.0%19.4%18.2%15.2%
Customer B28.8%17.5%26.7%13.7%
Customer C18.8%13.3%20.0%*
Customer D13.2%12.2%13.7%10.1%
Customer E15.0%*15.8%*
*Represents less than 10% and/or not a customer in the applicable period.
Total revenues, net is attributed to regions based on the location of our customers or license and collaboration partners.
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
U.S.91.2 %64.7 %91.9 %47.7 %
Europe, Middle East, and Africa (EMEA)8.1 %31.7 %7.2 %49.4 %
Asia-Pacific (APAC)0.7 %3.6 %0.9 %2.9 %
   Total100.0 %100.0 %100.0 %100.0 %
Summary of Other Current Liabilities
Other current liabilities presented on the condensed consolidated balance sheets consisted of the following balances:
June 30, 2026December 31, 2025
(in thousands)
Accrued rebates and other related costs$79,967 $45,909 
Accrued commercial52,167 35,773 
Deferred royalty obligations, current portion (1)29,283 11,221 
Accrued interest16,532 14,411 
Accrued professional services7,778 3,665 
Other accrued liabilities6,459 9,243 
Total other current liabilities$192,186 $120,222 
(1)Including related party amounts of $5,626 and $2,003 as of June 30, 2026 and December 31, 2025, respectively (as described in Note 9).
Summary of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss
The following table summarizes our segment information for significant operating expenses:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(in thousands)(in thousands)
Revenues:
Net product revenue$222,440 $71,501 $403,036 $108,240 
License and services revenue5,804 37,440 10,223 117,130 
Royalty revenue15,432 1,624 24,932 1,828 
Total revenues, net243,676 110,565 438,191 227,198 
Operating costs and expenses:
Cost of revenues:
Cost of goods sold10,528 2,848 18,260 4,882 
Cost of license, services, and royalty revenue4,518 805 6,725 1,410 
Total cost of revenues15,046 3,653 24,985 6,292 
Research and development by significant program:
Acoramidis for the treatment of ATTR-CM and primary
   prevention in asymptomatic carriers of a pathogenic TTR variant		36,522 28,269 67,913 52,661 
Infigratinib for achondroplasia and hypochondroplasia35,460 30,191 70,993 58,125 
BBP-418 for LGMD2I/R926,653 11,243 42,261 25,452 
Encaleret for ADH124,079 13,128 44,507 28,587 
Other development programs6,763 10,536 13,523 21,966 
Other research programs19,971 17,864 36,887 35,871 
Total segment research and development149,448 111,231 276,084 222,662 
Selling, general and administrative186,261 129,154 350,157 235,519 
Restructuring, impairment, and related charges— 805 — 1,375 
Total operating costs and expenses350,755 244,843 651,226 465,848 
Loss from operations(107,079)(134,278)(213,035)(238,650)
Other income (expense), net:
Interest income6,659 3,898 12,905 9,283 
Interest expense(13,278)(11,607)(26,220)(29,728)
Noncash interest expense on deferred royalty obligations (1)(41,345)(26,030)(81,218)(50,050)
Loss on extinguishment of debt— — — (21,155)
Net loss from equity method investments(6,435)(20,189)(24,718)(35,745)
Other income, net5,587 6,548 9,840 14,779 
Total other expense, net(48,812)(47,380)(109,411)(112,616)
Loss before income taxes(155,891)(181,658)(322,446)(351,266)
Provision for income taxes— 2,100 — 2,100 
Net loss(155,891)(183,758)(322,446)(353,366)
Net loss attributable to redeemable convertible noncontrolling
   interests and noncontrolling interests		3,675 1,855 6,187 4,041 
Segment net loss attributable to common stockholders of BridgeBio$(152,216)$(181,903)$(316,259)$(349,325)
(1)Including related party amounts of $(5,575) and $(10,936), respectively, for the three and six months ended June 30, 2026 (as described in Note 9).
Schedule of Inventories Presented on Condensed Consolidated Balance Sheet
Inventories presented on the condensed consolidated balance sheet consisted of the following balances:
June 30, 2026December 31, 2025
(in thousands)
Raw materials$27,853 $14,997 
Work in process16,700 6,104 
Finished goods11,119 6,509 
Inventory reserve(2,830)(857)
   Total inventories$52,842 $26,753